search
Back to results

Development of a Method to Measure mRNA Levels in Skin Samples

Primary Purpose

Healthy, Atopic Dermatitis Eczema, Psoriasis

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Skin squame collection
Tape strip collection
Tape strip and skin biopsy collection
Sponsored by
Innovaderm Research Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Healthy focused on measuring Skin squames, Tape stripping, Skin biopsy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Subject, male or female, aged 18 years or older at the time of consent.
  • Female subjects of childbearing potential had a negative urine pregnancy test at the screening visit.
  • Subjects had to be able and willing to provide written informed consent and comply with the requirements of the study protocol. Consent was obtained prior to any study-related procedures.

    *Special inclusion criteria for volunteers with atopic dermatitis or psoriasis:

  • Patient had a history of atopic dermatitis or psoriasis.
  • Patient with psoriasis had a Physician's Global Assessment (PGA) score of ≥2 at Day 0.
  • Patients with atopic dermatitis had an Investigator's Global Assessment (IGA) score of ≥2 at Day 0.

Exclusion Criteria:

  • Female subject was pregnant or breastfeeding.
  • Subject was participating in a clinical trial with an experimental drug or device or had participated in a clinical trial with an experimental drug or device within the last 4 weeks of the collection day (Day 0).
  • Subject was known to have hepatitis B or hepatitis C viral infection.
  • Subject was known to have immune deficiency or was immunocompromised.
  • Subject had used systemic medication, medical devices, UVB or PUVA therapy or natural health products to treat atopic dermatitis or psoriasis on the areas to be biopsied or tape stripped within 4 weeks of the collection day (Day 0).
  • Subject had used oral, intravenous steroids, or immunosuppressive medication within 4 weeks of the collection day (Day 0). Subject had used intramuscular or intra-lesional or intra-articular steroids or immunosuppressive medication on the areas to be biopsied or tape stripped within 4 weeks of the collection day (Day 0).
  • Subject had used a biologic within 12 weeks or 5 half-lives of the collection day (Day 0), whichever was longer.
  • Subject had used topical medication, natural health products or medical devices to treat atopic dermatitis or psoriasis on the areas to be tape stripped or biopsied within 2 weeks of the collection day (Day 0).

    *Only for subjects who underwent skin biopsy:

  • Subject had a known hypersensitivity/allergy to lidocaine.
  • Subject had a history of hypertrophic scarring or keloid formation in scars or suture sites.
  • Subject was taking anti-coagulant medication (e.g. heparin, low molecular weight [LMW]-heparin, warfarin, anti-platelets [nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin (equal or lower than 81 mg) were not considered anti-platelets]) or had a contraindication to skin biopsies.

Sites / Locations

  • Innovaderm Research, Inc.

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Skin sample collection

Arm Description

Skin sample collection for gene expression analyses.

Outcomes

Primary Outcome Measures

Expression of skin biomarkers
Gene expression of epidermal cytokines and chemokines.

Secondary Outcome Measures

Full Information

First Posted
August 28, 2020
Last Updated
September 2, 2020
Sponsor
Innovaderm Research Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04537468
Brief Title
Development of a Method to Measure mRNA Levels in Skin Samples
Official Title
Development of a Method to Measure mRNA Levels From the Skin of Patients With Psoriasis and Patients With Atopic Dermatitis Using Tape Strippings
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
May 11, 2017 (Actual)
Primary Completion Date
May 22, 2019 (Actual)
Study Completion Date
October 2, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Innovaderm Research Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study was to develop a non-invasive method to measure mRNA levels using tape stripping on the skin of patients with psoriasis and patients with atopic dermatitis.
Detailed Description
Three sequential groups of subjects were recruited in this study for: 1) skin squame collection; 2) tape strip collection; and 3) tape strip and skin biopsy collection in the aim of identifying the most optimal method for measuring the mRNA levels of skin biomarkers in tape strip samples.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Atopic Dermatitis Eczema, Psoriasis
Keywords
Skin squames, Tape stripping, Skin biopsy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
The study consisted of 3 sequential groups: Collection of skin squames by scraping. Collection of tape strip samples. Collection of tape strip samples and skin biopsies.
Masking
None (Open Label)
Allocation
N/A
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Skin sample collection
Arm Type
Other
Arm Description
Skin sample collection for gene expression analyses.
Intervention Type
Other
Intervention Name(s)
Skin squame collection
Intervention Description
Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.
Intervention Type
Other
Intervention Name(s)
Tape strip collection
Intervention Description
The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.
Intervention Type
Other
Intervention Name(s)
Tape strip and skin biopsy collection
Intervention Description
Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
Primary Outcome Measure Information:
Title
Expression of skin biomarkers
Description
Gene expression of epidermal cytokines and chemokines.
Time Frame
Day 0

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subject, male or female, aged 18 years or older at the time of consent. Female subjects of childbearing potential had a negative urine pregnancy test at the screening visit. Subjects had to be able and willing to provide written informed consent and comply with the requirements of the study protocol. Consent was obtained prior to any study-related procedures. *Special inclusion criteria for volunteers with atopic dermatitis or psoriasis: Patient had a history of atopic dermatitis or psoriasis. Patient with psoriasis had a Physician's Global Assessment (PGA) score of ≥2 at Day 0. Patients with atopic dermatitis had an Investigator's Global Assessment (IGA) score of ≥2 at Day 0. Exclusion Criteria: Female subject was pregnant or breastfeeding. Subject was participating in a clinical trial with an experimental drug or device or had participated in a clinical trial with an experimental drug or device within the last 4 weeks of the collection day (Day 0). Subject was known to have hepatitis B or hepatitis C viral infection. Subject was known to have immune deficiency or was immunocompromised. Subject had used systemic medication, medical devices, UVB or PUVA therapy or natural health products to treat atopic dermatitis or psoriasis on the areas to be biopsied or tape stripped within 4 weeks of the collection day (Day 0). Subject had used oral, intravenous steroids, or immunosuppressive medication within 4 weeks of the collection day (Day 0). Subject had used intramuscular or intra-lesional or intra-articular steroids or immunosuppressive medication on the areas to be biopsied or tape stripped within 4 weeks of the collection day (Day 0). Subject had used a biologic within 12 weeks or 5 half-lives of the collection day (Day 0), whichever was longer. Subject had used topical medication, natural health products or medical devices to treat atopic dermatitis or psoriasis on the areas to be tape stripped or biopsied within 2 weeks of the collection day (Day 0). *Only for subjects who underwent skin biopsy: Subject had a known hypersensitivity/allergy to lidocaine. Subject had a history of hypertrophic scarring or keloid formation in scars or suture sites. Subject was taking anti-coagulant medication (e.g. heparin, low molecular weight [LMW]-heparin, warfarin, anti-platelets [nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin (equal or lower than 81 mg) were not considered anti-platelets]) or had a contraindication to skin biopsies.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Bissonnette, MD
Organizational Affiliation
Innovaderm Research Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Innovaderm Research, Inc.
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2X 2V1
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32709423
Citation
He H, Bissonnette R, Wu J, Diaz A, Saint-Cyr Proulx E, Maari C, Jack C, Louis M, Estrada Y, Krueger JG, Zhang N, Pavel AB, Guttman-Yassky E. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021 Jan;147(1):199-212. doi: 10.1016/j.jaci.2020.05.048. Epub 2020 Jul 21.
Results Reference
result

Learn more about this trial

Development of a Method to Measure mRNA Levels in Skin Samples

We'll reach out to this number within 24 hrs